Glycologix is developing a non-systemic, highly cross-linked chondroitin sulfate (CS) based biopolymer platform for soft tissue protection and repair which is focused on a broad range of unmet needs. Our platform of biopolymers mimics naturally occurring proteoglycans (PGs) and can be tailored to protect and repair specific tissue types.
PGs in human tissue perform critical biologic functions including providing hydration, barrier function, structural support, and lubrication. In nature, PGs are structured with small single-chain branches of biopolymers from the family of sulfated glycosaminoglycans, including CS. In the matrix that surrounds human cells, PGs maintain hydration and affect the activity and stability of proteins within the matrix.
Our compounds are branched, high molecular weight molecules synthetically prepared from many small single chain sulfated glycosaminoglycans.
Glycologix’s initial molecule, based on chondroitin sulfate, is the first soluble high molecular weight (>1,000 kDa) sulfated GAG material.
It mimics important features of PG structure by presenting a multi-pronged array of chains providing osmotic hydration and high affinity to biological surfaces in a way that is not possible for small single-chain GGs. Our compounds can be tailored to specific tissue types, creating multiple licensing/ strategic opportunities. They are also quickly and easily manufactured using widely available manufacturing materials and equipment.
Utilizing our technology platform, therapeutic advances are possible in a number of soft tissue conditions such as:
interstitial cystitis/bladder pain syndrome, dry eye/ophthalmic, surgical adhesion prevention, osteoarthritis, spinal disc disease, and wound repair.